Cargando…

Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis

BACKGROUND AND AIMS: Vedolizumab was shown to be safe and effective for the treatment of Crohn’s disease [CD] and ulcerative colitis [UC] in the GEMINI Long-Term Safety [LTS] study. The vedolizumab Extended Access Program [XAP] provides patients with continued treatment. This XAP pharmacokinetics [P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vermeire, Séverine, Lukáš, Milan, Magro, Fernando, Adsul, Shashi, Lindner, Dirk, Rosario, Maria, Roth, Jeannine, Danese, Silvio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476636/ https://www.ncbi.nlm.nih.gov/pubmed/32060515 http://dx.doi.org/10.1093/ecco-jcc/jjaa027

Ejemplares similares

Vedolizumab treatment persistence and safety in a 2‐year data analysis of an extended access programme
por: Danese, Silvio, et al.
Publicado: (2020)

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis
por: Ryan, Caitriona, et al.
Publicado: (2018)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer
por: Dubé-Pelletier, Maude, et al.
Publicado: (2023)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Which is the best schedule of autologous blood storage for pre-operative AIS patients? Every week or every 2 weeks
por: Tamai, Koji, et al.
Publicado: (2015)

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria
por: Peipert, John Devin, et al.
Publicado: (2020)

As every year, 2016 ended with the Council Week
por: Staff Association
Publicado: (2017)

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
por: Okamoto, Hiroyuki, et al.
Publicado: (2021)

Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis
por: Saito, Daisuke, et al.
Publicado: (2021)

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks
por: Kerbusch, T, et al.
Publicado: (2004)

‘I Know it was Every Week, but I Can't be Sure if it was Every Day: Domestic Violence and Women with Learning Disabilities
por: McCarthy, Michelle, et al.
Publicado: (2016)

Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer
por: Melotek, James M., et al.
Publicado: (2016)

Health benefits of late-onset metformin treatment every other week in mice
por: Alfaras, Irene, et al.
Publicado: (2017)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
por: McGarvey, November, et al.
Publicado: (2015)

Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
por: Ooi, Choon Jin, et al.
Publicado: (2021)

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)
por: Butzkueven, Helmut, et al.
Publicado: (2021)

Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study
por: Banerjee, Rupa, et al.
Publicado: (2021)

Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma
por: Fayette, Jérôme, et al.
Publicado: (2015)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
por: Braun, Jürgen, et al.
Publicado: (2011)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

Should We Have a Universal 1-Week Lockdown Every Year?
por: Alpert, Joseph S., et al.
Publicado: (2020)

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial
por: Vermeire, Séverine, et al.
Publicado: (2021)

One Bulletin printed every two weeks, but updated weekly on-line, equals the same quantity of information as a weekly printed Bulletin.
por: Stephane Viollet
Publicado: (2005)

Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis
por: Landry, Kara K, et al.
Publicado: (2022)

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
por: Gilroy, Leah, et al.
Publicado: (2014)

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial
por: Panés, Julian, et al.
Publicado: (2023)

Phase I study of gemcitabine using a once every 2 weeks schedule.
por: Vermorken, J. B., et al.
Publicado: (1997)

Selective biologics for ulcerative colitis and Crohn’s disease – clinical utility of vedolizumab
por: Petkau, Jill MV, et al.
Publicado: (2016)

Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid Tumors
por: Yamada, Kazuhiko, et al.
Publicado: (2010)

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
por: Glaspy, J A, et al.
Publicado: (2002)

Every-Day Lessons from Every-Day Cases
por: Reed, Charles A. L.
Publicado: (1908)

Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis
por: Morita, Akimichi, et al.
Publicado: (2021)

Fosaprepitant Weekly vs Every 3 Weeks for the Prevention of Concurrent Chemoradiotherapy–Induced Nausea and Vomiting: A Pilot Randomized Clinical Trial
por: Yang, Qi, et al.
Publicado: (2023)

Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn’s Disease: Results from the Phase 2 HUBBLE Study
por: Hyams, Jeffrey S, et al.
Publicado: (2022)

Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age
por: Yajnik, Vijay, et al.
Publicado: (2017)

Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis
por: Miyoshi, Jun, et al.
Publicado: (2021)

Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin
por: Müller-Wieland, Dirk, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dkcom1p4skb129jktn6qme9bd8